Artificial intelligence in the pharmaceutical industry of Ukraine: prospects for future development

Alina Savchuk [1*], Iryna Borysiuk [2], Tamara Mahanova [3], Tatiana Ihnatova[4]

[1] NSC "Institute of Biology and Medicine", KNU named after Taras Shevchenko, Kyiv, Ukraine, https://orcid.org/0000-0003-3188-3064

[2] International Humanitarian University, Odessa, Ukraine, https://orcid.org/0000-0003-2824-9118

[3]Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine, https://orcid.org/0000-0001-7008-3102

[4] Pylyp Orlyk International Classical University, Mykolaiv, Ukraine, https://orcid.org/0000-0002-7229-6715

Abstract

Artificial Intelligence (AI) has emerged as a powerful tool with the potential to revolutionise industries across the globe. Among the many sectors AI is making a profound impact on, the pharmaceutical industry is as well experiencing significant transformations.

Aims: To assess the Current State of AI Adoption, to Examine the Regulatory and Ethical Landscape of AI Implementation and to Identify Opportunities and Challenges in Ukraine.

Methodology: A descriptive cross-sectional study

Results: Currently, 4.1 billion people worldwide have sustainable Internet access, and 2.8 billion people make purchases online. This data highlights the significant global growth of Internet users and the increasing popularity of online shopping. The average digital user is now aged between 25 and 44. It indicates a shift in the age group of individuals actively using digital technologies. This demographic change has implications for businesses targeting digital consumers. Ukraine's pharmaceutical industry lags behind neighboring countries like the Czech Republic, Russia, and Poland in terms of AI utilisation, with only 10 publications related to AI in pharmaceuticals. This suggests a potential gap in research funding, industry investment, or academic expertise that needs to be addressed. Several prominent pharmaceutical companies in Ukraine are actively integrating AI and technology into their operations. These companies are focusing on various aspects, including drug discovery, diagnostics, innovation hubs, and investments in genetics and genomics. This highlights the industry's increasing adoption of AI. The challenges include the need for high-quality data, the difficulty in recruiting AI experts, regulatory compliance, and the financial constraints of funding AI initiatives. These challenges are critical considerations for pharmaceutical firms looking to leverage AI in their operations.

Scientific Novelty: Artificial Intelligence (AI) has emerged as a powerful tool with the potential to revolutionise industries .

Conclusion: These results collectively provide insights into the evolving landscape of digital technology.

Introduction

The term "artificial intelligence" (AI) refers to a strong instrument that has just come into its own and has the potential to disrupt several sectors throughout the world. Among many sectors AI is making a profound impact on, the pharmaceutical industry is experiencing significant transformations. In the context of Ukraine, a country with a burgeoning pharmaceutical sector and a growing interest in technology, AI's role in shaping the future of the pharmaceutical industry is of great importance [1]. Before diving into the prospects of AI in the Ukrainian pharmaceutical industry, it's essential to understand the current state of this sector. Ukraine has a rich history of pharmaceutical production and research, with many domestic and international companies operating within its borders. The industry significantly contributes to the country's economy, and Ukraine has been working to strengthen its pharmaceutical capabilities to meet domestic healthcare needs and expand into global markets [2].

However, like many countries, Ukraine faces challenges in pharmaceutical research, drug development, and healthcare delivery. These challenges include the need for more efficient drug discovery processes, improved healthcare infrastructure, and greater accessibility to quality healthcare services for its citizens. AI has the potential to address many of these challenges and drive substantial progress in the pharmaceutical sector [3]. The creation of new drugs is one of the pharmaceutical industry's most promising applications for artificial intelligence. Traditional drug discovery methods are expensive, time-consuming, and can provide ambiguous findings. AI can significantly accelerate this process by analysing vast datasets, identifying potential drug candidates, predicting their efficacy, and even optimising molecular structures [4].

In Ukraine, research institutions and pharmaceutical companies are increasingly adopting AI-driven approaches to drug discovery. Collaborations between academia and industry have led to the development of AI-powered tools that analyse biological data, conduct virtual screenings, and model molecular interactions. These advancements hold the potential to not only speed up the drug development but also reduce the costs and increase the likelihood of successful outcomes [5]. Ensuring that pharmaceutical products meet regulatory standards is a crucial aspect of the industry. AI can enhance regulatory processes by streamlining compliance checks, monitoring manufacturing processes in real-time, and identifying potential quality issues before they become critical. In Ukraine, implementing AI-driven solutions in regulatory processes can lead to a better quality control and a more efficient approval process for pharmaceutical products, ultimately improving the industry's competitiveness on the global stage [6].

Beyond the drug development, AI can also play a pivotal role in improving healthcare delivery and patient care in Ukraine. Telemedicine, remote patient monitoring, and predictive analytics are areas where AI can make healthcare services more accessible and efficient, especially in rural and under-served areas. Ukraine's vast geographical landscape presents unique challenges in healthcare access, and AI-powered telehealth solutions can bridge these gaps. Patients in remote areas can receive timely medical consultations, and healthcare providers can better allocate resources and manage patient data with AI's assistance. This not only improves patient outcomes but also reduces the burden on healthcare facilities, making the healthcare system more resilient [7].

As AI heavily relies on data, ensuring the privacy and security of patient and research data is paramount. Adequate regulations and safeguards need to be in place in order to protect sensitive information. Building a workforce with the necessary AI skills and expertise is essential. Investment in education and training programs is crucial to harness the full potential of AI. Developing clear and adaptable regulatory frameworks for AI in healthcare and pharmaceuticals is vital. This ensures that innovations are safe, effective, and in compliance with international standards. As AI becomes more integrated into healthcare, ethical considerations surrounding decision-making, transparency, and bias must be addressed to maintain public trust [8].

The utilisation of AI in the pharmaceutical industry of Ukraine holds immense promise for the future. AI-powered solutions have the potential to greatly enhance the sector's overall efficiency and efficacy in a variety of areas, including medication research and the delivery of healthcare services. By addressing current challenges and considering ethical and regulatory implications, Ukraine can position itself as a leader in AI-driven pharmaceutical innovation, ultimately benefiting its economy and the health and well-being of its citizens. As the country continues to invest in technology and research, the synergy between AI and the pharmaceutical industry in Ukraine will undoubtedly shape the future of healthcare and drug development in the region [9].

Research Problem

The research problem for the study on "Artificial Intelligence in the Pharmaceutical Industry of Ukraine: Prospects for Future Development" can be framed as follows:

The pharmaceutical industry in Ukraine stands at a critical juncture, seeking to enhance its competitiveness in the global market while addressing domestic healthcare challenges. In this context, the integration of Artificial Intelligence (AI) holds great promise, but it also presents significant challenges. The research problem at hand is to investigate the current status of AI adoption in the Ukrainian pharmaceutical sector and assess its potential to transform drug discovery, development, regulatory processes, and healthcare delivery. Moreover, the study aims to identify the key barriers, regulatory complexities, ethical considerations, and opportunities that surround the

utilisation of AI in this industry, ultimately informing strategies for sustainable growth and innovation within the Ukrainian pharmaceutical landscape.

Research Focus

This study investigates the transformative potential of artificial intelligence (AI) within the Ukrainian pharmaceutical industry, with a comprehensive exploration of its current status, regulatory landscape, ethical implications, and practical applications. By examining AI's impact on drug discovery, development, production, and healthcare delivery, as well as the opportunities and challenges for collaboration between domestic stakeholders and international partners, this research aims to provide valuable insights into the prospects for AI-driven advancements in the Ukrainian pharmaceutical sector and its potential contribution to enhancing the healthcare access and innovation in the country.

Research Aim and Research Questions

Research Aims and Objectives were to determine the:

1. The current state of AI use in the pharmaceutical sector in Ukraine.

2. Regulatory and Ethical Landscape of AI Implementation in Pharmaceuticals in Ukraine.

3. The utilisation and effectiveness of AI use in Pharmaceutical Industry.

4. Opportunities and challenges for using AI in pharmaceutical Industry.

Research Questions

1. What is the current level of AI adoption in the Ukrainian pharmaceutical industry?

2. How does the regulatory framework in Ukraine address the implementation of AI in the pharmaceutical sector, and what ethical considerations are associated with AI adoption in this industry?

3. To what extent is AI currently utilised in the Ukrainian pharmaceutical industry, and what evidence is there regarding its effectiveness in improving various aspects of pharmaceutical operations?

4. What opportunities exist for the use of AI in the pharmaceutical industry in Ukraine, and what are the primary challenges and obstacles that hinder its widespread implementation?

These research questions provided a foundation for a comprehensive study that could offer valuable insights into the prospects and challenges of integrating AI into the pharmaceutical industry of Ukraine.

Research Methodology

General Background

The pharmaceutical industry represents a critical pillar of Ukraine's economy and plays a significant role in the country's healthcare infrastructure. Over the years, Ukraine has made strides in pharmaceutical research, production, and healthcare delivery. However, like many nations, Ukraine faces a set of complex challenges within this sector, ranging from the need for more efficient drug discovery processes to ensuring equitable access to quality healthcare services.

In tandem with these challenges, there has been a global surge in the adoption of Artificial Intelligence (AI) across various industries, promising substantial advancements in efficiency, productivity, and innovation. The intersection of AI and the pharmaceutical industry has garnered considerable attention worldwide, with AI technologies offering transformative potential in nearly every facet of pharmaceutical research, development, and healthcare.

Within the Ukrainian context, there is growing recognition of the benefits that AI can bring to the pharmaceutical sector. Stakeholders, including academic institutions, pharmaceutical companies, regulatory bodies, and healthcare providers, are increasingly exploring the integration of AI into their operations. This burgeoning interest in AI presents a pivotal opportunity for Ukraine to accelerate its pharmaceutical capabilities, to improve the healthcare delivery, and solidify its position as a competitive player in the global pharmaceutical landscape.

To leverage effectively the AI, Ukraine must navigate various complexities, including ethical considerations, regulatory frameworks, data privacy concerns, and the need for a skilled workforce capable of harnessing AI's potential. Additionally, the country needs to establish partnerships and collaborations with international entities, leveraging global expertise in AI applications in healthcare and pharmaceuticals.

This study intends to provide a thorough analysis of how AI adoption is now progressing within the Ukrainian pharmaceutical sector, investigate its effects on drug development, research, regulatory procedures, and healthcare delivery, and look at the difficulties and potential that still lie ahead. By doing so, it seeks to contribute to the understanding of how Ukraine can effectively utilise AI to bolster its pharmaceutical sector, foster innovation, and enhance healthcare outcomes for its population.

Data Analysis

In this research, a descriptive cross sectional approach was used. There was no analysis carried whatsoever. Both a table and some figures are used to show the data.

Research Results

Table 1 presents a snapshot of the current state of global internet usage, revealing that approximately 4.1 billion people worldwide enjoy reliable internet access. Notably, this number continues to surge by an impressive 100,000 users daily, underscoring the relentless growth of digital connectivity. Of these online denizens, a substantial 2.8 billion individuals engage in e-commerce, highlighting the substantial reach of online shopping. One noteworthy trend emerging from this digital landscape is the shifting demographic of internet users. The average age of digital consumers is on the rise, with a predominant segment falling within the 25 to 44 age brackets. This demographic shift hints at evolving consumer behaviors and preferences, which businesses must adapt to remain competitive.

Table 1. Current status of AI in Ukraine Pharmaceuticals.

Variable	Frequency
Internet access is sustainable worldwide	4.1 billion
Users are increasing daily	1 million
People making purchases on the Internet	2.8 billion
Typical digital user is becoming older, presently between	25 and 44
Large pharmaceutical businesses in Ukraine have access to innovative digital technology.	Online consulting, Mobile applications, Online orders Record of customer purchases and Gamification of customer acquisition

Source: Authors' development based on Iryna et al. 2022 n.d.

Particularly Ukraine's pharmaceutical industry, has embraced various digital technologies to cater to its clientele. These advancements include online chat services for customer consultations, mobile applications, streamlined online ordering and product reservations, digital records of customer transactions, and innovative customer acquisition strategies like gamification. Among the sectors within the pharmaceutical industry, the retail segment stands out as particularly adept at monitoring and embracing digital transformation trends. This underscores the industry's commitment to leveraging technology for enhanced customer experiences and operational efficiency, ensuring that it remains at the forefront of the evolving digital landscape.

Figure 1 provides a clear depiction of the publication trend related to the utilisation of Artificial Intelligence (AI) within the pharmaceutical sector in Ukraine. It reveals a rather stark contrast between Ukraine and neighboring countries such as the Czech Republic, Russia, and Poland. Ukraine's output in this field stands at a mere 10 publications, a significantly lower number than what one might expect given the country's potential and the advancements seen in the surrounding regions. Several potential factors could contribute to this noticeable lag. Firstly, differences in research funding may play a critical role. Ukraine may not be allocating sufficient resources towards AI-driven pharmaceutical research when compared to its neighbors, limiting the scope and scale of research initiatives. Similarly, disparities in industry investment could be a key determinant. The pharmaceutical industry in Ukraine may not be as inclined or capable of investing in AI technologies and infrastructure as those in neighboring nations, which might result in slower adoption.

Figure 1. Publication Trends of AI use in Ukrainian pharmaceuticals (Eastern Europe).

The academic expertise and collaboration could also be crucial factors. Ukraine may have fewer specialised experts and collaborative efforts in the field of AI within pharmaceuticals, impeding progress. To address this disparity, Ukraine may need to actively seek an increased investment, to foster collaboration among its academic institutions, research centers, and pharmaceutical companies, and to promote initiatives that encourage the integration of AI into pharmaceutical research and development. It is imperative for Ukraine to take proactive measures to bridge this gap and capitalise on the potential benefits that AI can offer in the pharmaceutical sector, ultimately ensuring its competitiveness in the global pharmaceutical landscape.

Table 2 shows that the pharmaceutical industry is undergoing a significant transformation, with many prominent companies incorporating advanced technologies, particularly artificial intelligence (AI), into their operations. Novartis stands out for its innovative approach, as it combines AI with satellite imagery for target and object recognition, a powerful tool for drug development. Johnson & Johnson is dedicated to accelerating drug discovery, especially for neglected tropical diseases, by utilising AI and developing automated diagnostic tools. AstraZeneca prioritises the discovery and delivery of new medicines, with its iLab serving as a hub for innovative chemistry solutions. Bristol Myers Squibb focuses on all stages of drug development, from discovery to clinical trials.

Table 2. Status of Pharmaceutical Industries using AI in Ukraine.

No.	Company Name	Functions
1	Novartis	To create transformative medicines, integrate target and object recognition with satellite imagery
2	Johnson & Johnson	To speed up the drug discovery process, to develop automated diagnostic tools for NTDs
3	AstraZeneca	Discovery and delivery of potential new medicines, AstraZeneca iLab is a vehicle for innovation in chemistry
4	Bristol Myers Squibb	Drug discovery and development, clinical trials
5	GlaxoSmithKline	Drug discovery and development globally, investments in human genetics, functional genomics
6	Bayer	A hub for Pharma and Consumer Health products for the entire Ukrainian market
7	Sanofi	Drug development, clinical trial design, and manufacturing and supply candidates' efficacy in virtual patient groups
8	Roche	Drug discovery and development, data analytics, machine learning, and AI tools application in the pharmaceutical industry and digital pathology

GlaxoSmithKline invests in global drug discovery, with a keen interest in human genetics and functional genomics. Bayer concentrates on Pharma and Consumer Health products in the Ukrainian market. Sanofi is deeply involved in drug development, clinical trial design, and manufacturing, even exploring the efficacy of candidates in virtual patient groups. Lastly, Roche is committed to drug discovery and development, harnessing the power of data analytics, machine learning, and AI tools to advance the pharmaceutical industry, particularly in the realm of digital pathology. These companies collectively exemplify the pharmaceutical industry's increasing reliance on AI and technology to drive innovation and improve healthcare outcomes in Ukraine and beyond.

Table 3 provides a comprehensive overview of the critical considerations that Ukrainian pharmaceutical firms must carefully navigate when embarking on the path to integrating artificial intelligence (AI) into their drug design processes. First and foremost, it underscores the paramount importance of abundant and high-quality data. AI in drug design heavily relies on extensive datasets for training algorithms and making accurate predictions. Ukrainian companies need to invest in robust data collection, curation, and storage mechanisms to ensure the success of their AI-driven initiatives. Recruiting top-tier AI experts emerges as a pivotal challenge. Developing and implementing AI models for drug design is a highly specialised field, demanding a unique skill set. The scarcity of qualified AI professionals in Ukraine may pose an obstacle, and firms should consider strategies for talent acquisition, including partnerships with academic institutions or international collaborations.

Table 3. Challenges with AI use in Ukrainian pharmaceuticals.

Variable	Description
Access to good quality and extensive data	AI drug design requires abundant, high-quality data for accurate results.
Lack of expertise	Ukrainian pharma firms may struggle to recruit AI experts for complex tasks.
Regulatory oversight	FDA seeks public input on AI in drug manufacturing; Ukrainian compliance concerns.
Cost	Ukrainian pharma firms may struggle with costly AI tech funding.

Source: Authors' development based on Inside Tech Media n.d.

On the regulatory front, aligning AI practices with evolving regulations, particularly those laid out by the FDA, is of paramount importance. Ensuring compliance with international standards is essential not only for gaining market

access but also for upholding patient safety and data integrity. Ukrainian pharmaceutical firms must proactively engage with regulatory authorities and stay abreast of evolving guidelines to avoid any legal or operational complications. Lastly, the financial aspect cannot be overlooked. Implementing AI technology in drug design can be a costly endeavor. Ukrainian firms may encounter challenges in securing the necessary funding for research, infrastructure, and talent acquisition. Strategic planning, exploring public-private partnerships, and seeking funding opportunities through grants or investment partnerships could help mitigate these financial hurdles.

Discussion

Digital technologies are increasingly being used in Ukraine's pharmaceutical industry. The pharmaceutical industry has gone digital, and as a result, there are now online chats for client consultation, mobile apps, online orders, and products reservations available, all of which may enhance the consumer's felicity. The use of gamification of customer acquisition can help attract new customers and retain existing ones. Digital transformation can personalize customer experiences, optimise sales strategies, and identify emerging market trends by leveraging real-time insights [10].

The publication trend of AI use in the pharmaceutical industry in Ukraine, which lags behind neighboring countries like the Czech Republic, Russia, and Poland, with only 10 publications. This suggests that Ukraine may be less advanced in harnessing AI for pharmaceutical research and development, potentially due to differences in research funding, industry investment, or academic expertise. Addressing this gap may require increased investment, collaboration, and a more concerted effort to catch up with its regional counterparts in leveraging AI's potential in the pharmaceutical sector.

The European pharmaceutical sector expresses its support for the Ukrainian people. When confronted with a serious crisis, Europe may take advantage of its size and act quickly, as seen by its first reaction to the invasion of Ukraine. More than 200 clinical trial locations might be impacted by the Russian invasion of Ukraine. As the conflict in Ukraine continues, the nation's illness burden shifts and the healthcare system deteriorate. As AI technology develops at a dizzying pace, safety issues increase more quickly than solutions can be developed. Due of its corporate and technological disparity with other major countries, Europe is now experiencing a slow-motion competitiveness crisis that has been developing covertly over the last 20 years [11–13].

Overall, while there are positive developments in Europe's response to the war in Ukraine and its ability to leverage its scale, there are also negative impacts of the conflict on Ukraine's healthcare infrastructure and clinical trials. Additionally, the rapid advancement of AI technology poses safety risks that need to be addressed, and Europe is facing a competitiveness crisis that requires a concerted effort to address. The review also describes how several prominent pharmaceutical companies are utilising AI and technology in their operations. Novartis is integrating target and object recognition with satellite imagery. Johnson & Johnson is leveraging AI to expedite drug discovery and develop automated diagnostic tools for neglected tropical diseases. AstraZeneca's iLab serves as an innovation hub for chemistry. GlaxoSmithKline is investing in human genetics and functional genomics. Roche is applying data analytics, machine learning, and AI tools to the pharmaceutical industry and digital pathology. The paragraph does not mention any negative points about the companies' use of AI and technology [14,15].

Overall, the pharmaceutical sector might undergo a revolution thanks to the application of AI and technology in drug research and development, which would result in quicker and more effective medication development. However, the access to good quality and extensive data is crucial for the AI systems to provide accurate results. Pharmaceutical companies need to rewire their tech, tools, and operating models to fully leverage the benefits of AI and technology. The integration of AI into drug design in the Ukrainian pharmaceutical industry presents both opportunities and challenges. Artificial intelligence may assist speed up the process of drug development by making predictions about the effectiveness and safety of new medication candidates. This may result in the quicker development of new treatments as well as a possible reduction in prices. Increased productivity. AI may help pharmaceutical businesses become more productive by automating certain operations and decreasing the need for human labor. AI may assist in identifying patient subgroups that may react better to certain medications, resulting in more individualised treatment choices and better patient outcomes [16,17].

However, there are also several challenges associated with integrating AI into drug design in the Ukrainian pharmaceutical industry. Accurate AI-driven results require abundant, high-quality data. Obtaining such data can be challenging, particularly in developing countries like Ukraine. Handling complex AI tasks requires specialised expertise, and recruiting such experts can be difficult. Regulatory oversight, particularly the FDA's interest and Ukrainian compliance concerns, underscores the importance of aligning AI practices with evolving regulations. Implementing AI technology initiatives can be costly, and Ukrainian pharma firms may face challenges in funding such initiatives [18–20].

Overall, the integration of AI into drug design in the Ukrainian pharmaceutical industry presents both opportunities and challenges. While AI has the potential to improve the drug discovery and development, to

increase productivity, and improve patient outcomes, challenges related to data quality and quantity, recruiting AI experts, regulatory compliance, and costs must be addressed.

Conclusions and Implications

1. The digitalisation of the pharmaceutical business in Ukraine has brought about several positive changes, including enhanced customer experiences through online consultations, mobile applications, and online ordering. The incorporation of gamification can further boost customer engagement. Personalisation and real-time insights are poised to optimise sales strategies and identify market trends.

2. The limited number of AI-related publications in Ukraine compared to neighboring countries suggests a gap in harnessing AI for pharmaceutical research and development. Addressing this gap will necessitate increased investment, collaboration, and a concerted effort to catch up with regional counterparts.

3. Europe has shown solidarity with Ukraine in the face of the Russian invasion. However, this conflict has disrupted clinical trials and eroded healthcare infrastructure within Ukraine. The rapid advancement of AI technology introduces safety risks that need careful consideration.

4. Europe is experiencing a long-term competitiveness crisis in terms of corporate and technology gaps compared to other major regions. Addressing this crisis requires proactive efforts to bridge these gaps.

5. Several prominent pharmaceutical companies are actively utilising AI and technology in various aspects of their operations. While the passage highlights their innovative approaches, it does not mention any negative aspects or challenges they might face in implementing these technologies.

6. AI holds significant potential to revolutionize drug discovery and development, leading to faster, more efficient processes. It can also enable more personalised treatment options, improved patient outcomes, and increased productivity.

7. Integrating AI into the Ukrainian pharmaceutical industry presents challenges related to data quality and quantity, the recruitment of AI experts, regulatory compliance, and funding. Addressing these challenges is essential for successful implementation.

In summary, while there are promising opportunities for the pharmaceutical industry in Ukraine to benefit from digitalisation and AI, there are notable challenges that need to be addressed to fully realise these benefits. Collaboration between stakeholders, increased investment, and a commitment to data quality and regulatory compliance will be crucial in navigating this transformative journey. Europe's support for Ukraine amid conflict and its own competitiveness crisis also underscore the need for strategic planning and action in the pharmaceutical sector and beyond.

References

[1] Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today 2021;26:80. https://doi.org/10.1016/J.DRUDIS.2020.10.010.

[2] Chavda V, Anand K, Apostolopoulos V. Bioinformatics Tools for Pharmaceutical Drug Product Development. Bioinformatics Tools for Pharmaceutical Drug Product Development 2023:1–421. https://doi.org/10.1002/9781119865728.

[3] Filippova L V. Features of the development of higher pharmaceutical education in Ukraine. Pedagogical Sciences Reality and Perspectives 2021;2:97–100. https://doi.org/10.31392/NPU-NC.SERIES5.2021.84.2.20.

[4] Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers 2021;25:1315–60. https://doi.org/10.1007/S11030-021-10217-3.

[5] Kondratov IS, Moroz YS, Grygorenko OO, Tolmachev AA. The Ukrainian Factor in Early-Stage Drug Discovery in the Context of Russian Invasion: The Case of Enamine Ltd. ACS Med Chem Lett 2022;13:992. https://doi.org/10.1021/ACSMEDCHEMLETT.2C00211.

[6] Shevchenko AI, Glushkov Ave A, Bilokobylsky O V, Vakulenko MO, Dovbysh AS, Kazimir V V, et al. Regarding the draft strategy development of Artificial Intelligence in Ukraine. Jai.inUa n.d.;37:3057. https://doi.org/10.15407/jai2022.01.008.

[7] Haleem A, Javaid M, Singh RP, Suman R. Telemedicine for healthcare: Capabilities, features, barriers, and applications. Sensors International 2021;2:100117. https://doi.org/10.1016/J.SINTL.2021.100117.

[8] Vokinger KN, Gasser U. Regulating AI in medicine in the United States and Europe. Nat Mach Intell 2021;3:738. https://doi.org/10.1038/S42256-021-00386-Z.

[9] Kondratov IS, Moroz YS, Grygorenko OO, Tolmachev AA. The Ukrainian Factor in Early-Stage Drug Discovery in the Context of Russian Invasion: The Case of Enamine Ltd. ACS Med Chem Lett 2022;13:992. https://doi.org/10.1021/ACSMEDCHEMLETT.2C00211.

[10] Iryna T, Iryna B, Volodymyr M. Digitalization of Pharmaceutical Business in Ukraine. Res J Pharm Technol 2022;15:1555–9. https://doi.org/10.52711/0974-360X.2022.00259.

[11] Haque U, Naeem A, Wang S, Espinoza J, Holovanova I, Gutor T, et al. The human toll and humanitarian crisis of the Russia-Ukraine war: the first 162 days. BMJ Glob Health 2022;7. https://doi.org/10.1136/BMJGH-2022-009550.

[12] Eiben H, Hala L, Slipchuk V. The Current State of the Pharmaceutical Market of Ukraine, Quality Assurance and Falfication of Medicines. Pharmacia 2021;68:411–9. https://doi.org/10.3897/PHARMACIA.68.E64723.

[13]   Chumachenko D, Chumachenko T. Ukraine war: The humanitarian crisis in Kharkiv. The BMJ 2022. https://doi.org/10.1136/BMJ.O796.

[14]   Yang Z, Sun F, Chen DH, Wang ZQ, Wang CK, Li ZL, et al. Current spin polarization of a platform molecule with compression effect. Chinese Physics B 2022;31. https://doi.org/10.1088/1674-1056/AC4F53.

[15]   Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6. https://doi.org/10.1038/S41421-020-0156-0.

[16]   Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today 2021;26:80–93. https://doi.org/10.1016/J.DRUDIS.2020.10.010.

[17]   Xu Y, Liu X, Cao X, Huang C, Liu E, Qian S, et al. Artificial intelligence: A powerful paradigm for scientific research. Innovation 2021;2. https://doi.org/10.1016/J.XINN.2021.100179.

[18]   Gorgulla C, Boeszoermenyi A, Wang ZF, Fischer PD, Coote PW, Padmanabha Das KM, et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature 2020;580:663–8. https://doi.org/10.1038/S41586-020-2117-Z.

[19]   Kulkov I, Hellström M, Wikström K. Identifying the role of business accelerators in the developing business ecosystem: the life science sector. European Journal of Innovation Management 2020;24:1459–79. https://doi.org/10.1108/EJIM-04-2020-0139.

[20]   Kulkov I. The role of artificial intelligence in business transformation: A case of pharmaceutical companies. Technol Soc 2021;66:101629. https://doi.org/10.1016/J.TECHSOC.2021.101629.